Last updated: January 25, 2024
Sponsor: University of Colorado, Denver
Overall Status: Active - Not Recruiting
Phase
2/3
Condition
N/ATreatment
Weight loss diet
Semaglutide 3mg and 7mg [Rybelsus]
Clinical Study ID
NCT03919929
19-0636
1R01DK120612-01A1
Ages 12-21 Female
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Sedentary- less than 2 hours of moderate (jogging, swimming etc) exercise a week.
- BMI equal or greater than the 90th percentile for age and gender
- PCOS per the most stringent NIH criteria adapted for adolescents (irregular menses >12months post-menarche and clinical or biochemical hypertestosteronemia
- Participants cannot be on hormonal contraception, so participants should remainabstinent or use reliable non-hormonal contraception (e.g. copper IUD) for the entirestudy period. For participants who receive semaglutide, they should avoid pregnancyfor at least 2 months after stopping medication to avoid fetal exposure to themedication.
Exclusion
Exclusion Criteria:
- Diagnosed with or have a family history of medullary thyroid carcinoma (MTC) orMultiple Endocrine Neoplasia syndrome type 2 (MEN 2). Family history of medullarythyroid cancer or thyroid nodule palpated by endocrinologist at screening.
- Use of medications known to affect insulin sensitivity: metformin (cannot have beenused in the 3 months prior to screening), oral glucocorticoids within 10 days,atypical antipsychotics, immunosuppressant agents, HIV medications, hormonalcontraception (cannot have been used in the 6 months prior to screening). Dermal patchor vaginal ring contraception methods.Weight loss medications or stimulants. Use ofother products containing other GLP-1 agonists.
- Currently pregnant or breastfeeding women. Development of pregnancy during the studyperiod will necessitate withdrawal from the study.
- Severe illness requiring hospitalization within 60 days.
- Diabetes, defined as Hemoglobin A1C > 6.4%
- BMI percentile less than the 90th percentile for age and sex. Weight >325 lbs. or <84lbs.
- Anemia, defined as Hemoglobin < 11 mg/dL
- Diagnosed major psychiatric or developmental disorder limiting informed consent.
- Implanted metal devices that are not compatible with MRI
- Use of blood pressure medications.
- Known liver disease other than NAFLD or AST or ALT >100 IU/L.
- Personal history of pancreatitis
- Known renal disease of any severity or an eGFR at screening of <45ml/min/1.73m2
- History of severe GI disease (e.g. gastroparesis)
- History of gallstones
- Untreated thyroid disease
- History of hypersensitivity to semaglutide
- Other causes of hyperandrogenism (example: tumor, CAH) or amenorrhea (untreatedthyroid disease, tumor, primary ovarian failure, prolactinoma).
- Active symptoms or undergoing treatment for anorexia nervosa or binging/purgingdisorder
Study Design
Total Participants: 60
Treatment Group(s): 2
Primary Treatment: Weight loss diet
Phase: 2/3
Study Start date:
May 03, 2019
Estimated Completion Date:
July 31, 2024
Study Description
Connect with a study center
University of Colorado Anshutz Medical Campus/Children's Hospital Colorado
Aurora, Colorado 80045
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.